中国医药
中國醫藥
중국의약
CHINA MEDICINE
2010年
8期
712-714
,共3页
张建斌%鹿梁燕%王素芳%吴丽丽
張建斌%鹿樑燕%王素芳%吳麗麗
장건빈%록량연%왕소방%오려려
脑梗死%蚓激酶胶囊%脑循环动力学参数
腦梗死%蚓激酶膠囊%腦循環動力學參數
뇌경사%인격매효낭%뇌순배동역학삼수
Cerebral infarction%Lumbrukinase capsule%Cerebrovascular dynamics index
目的 观察和研究蚓激酶胶囊治疗急性脑梗死患者的疗效及对脑循环动力学的影响.方法 采用随机、双盲和平行对照的方法,把82例患者分为对照组40例与蚓激酶胶囊组42例,同样接受脑梗死的基本治疗,而蚓激酶胶囊组加用蚓激酶胶囊.对2组治疗前、治疗后的脑神经功能缺损评分、脑循环动力学参数((CVDI)等进行对比.结果 ①神经功能缺损评分,蚓激酶胶囊组治疗前(10.85±3.26)与治疗后(5.04±1.89)相比,差异有统计学意义(P<0.01);对照组治疗前(10.62±3.28)与治疗后(6.12±1.76)相比,差异有统计学意义(P<0.01);蚓激酶胶囊组治疗有效率(90.50%)与对照组(77.5%)相比,差异有统计学意义(P<0.05).②蚓激酶胶囊组病灶一侧CVDI中,脑血流量及血流速度治疗后[(4.26±1.26)ml/s;(9.98±1.82)cm/s]较治疗前[(4.13±1.46)ml/s;(7.12±1.63)cm/s]显著增加(P<0.015),较对照组治疗后[(4.62±1.26)ml/s;(9.26±1.58)cm/s]亦有显著增加(P<0.05).脑血管外周阻力及临界压力蚓激酶胶囊组和对照组治疗后[(1826±258)Pa.s/ml;(6.02±1.84)kPa;(1926±253)Pa.s/ml;(7.03±1.43)kPa]较治疗前[(2132±323 Pa.s/ml),(7.26±1.68)kPa;(2058±278)Pa.s/ml,(7.84±1.36)kPa]明显降低(P<0.05).结论 蚓激酶胶囊治疗急性脑梗死患者疗效好,能明显改善脑血流灌注,降低脑循环阻力,减少神经功能缺损,从而达到治疗脑梗死的目的,作为脑梗死的治疗药物安全有效.
目的 觀察和研究蚓激酶膠囊治療急性腦梗死患者的療效及對腦循環動力學的影響.方法 採用隨機、雙盲和平行對照的方法,把82例患者分為對照組40例與蚓激酶膠囊組42例,同樣接受腦梗死的基本治療,而蚓激酶膠囊組加用蚓激酶膠囊.對2組治療前、治療後的腦神經功能缺損評分、腦循環動力學參數((CVDI)等進行對比.結果 ①神經功能缺損評分,蚓激酶膠囊組治療前(10.85±3.26)與治療後(5.04±1.89)相比,差異有統計學意義(P<0.01);對照組治療前(10.62±3.28)與治療後(6.12±1.76)相比,差異有統計學意義(P<0.01);蚓激酶膠囊組治療有效率(90.50%)與對照組(77.5%)相比,差異有統計學意義(P<0.05).②蚓激酶膠囊組病竈一側CVDI中,腦血流量及血流速度治療後[(4.26±1.26)ml/s;(9.98±1.82)cm/s]較治療前[(4.13±1.46)ml/s;(7.12±1.63)cm/s]顯著增加(P<0.015),較對照組治療後[(4.62±1.26)ml/s;(9.26±1.58)cm/s]亦有顯著增加(P<0.05).腦血管外週阻力及臨界壓力蚓激酶膠囊組和對照組治療後[(1826±258)Pa.s/ml;(6.02±1.84)kPa;(1926±253)Pa.s/ml;(7.03±1.43)kPa]較治療前[(2132±323 Pa.s/ml),(7.26±1.68)kPa;(2058±278)Pa.s/ml,(7.84±1.36)kPa]明顯降低(P<0.05).結論 蚓激酶膠囊治療急性腦梗死患者療效好,能明顯改善腦血流灌註,降低腦循環阻力,減少神經功能缺損,從而達到治療腦梗死的目的,作為腦梗死的治療藥物安全有效.
목적 관찰화연구인격매효낭치료급성뇌경사환자적료효급대뇌순배동역학적영향.방법 채용수궤、쌍맹화평행대조적방법,파82례환자분위대조조40례여인격매효낭조42례,동양접수뇌경사적기본치료,이인격매효낭조가용인격매효낭.대2조치료전、치료후적뇌신경공능결손평분、뇌순배동역학삼수((CVDI)등진행대비.결과 ①신경공능결손평분,인격매효낭조치료전(10.85±3.26)여치료후(5.04±1.89)상비,차이유통계학의의(P<0.01);대조조치료전(10.62±3.28)여치료후(6.12±1.76)상비,차이유통계학의의(P<0.01);인격매효낭조치료유효솔(90.50%)여대조조(77.5%)상비,차이유통계학의의(P<0.05).②인격매효낭조병조일측CVDI중,뇌혈류량급혈류속도치료후[(4.26±1.26)ml/s;(9.98±1.82)cm/s]교치료전[(4.13±1.46)ml/s;(7.12±1.63)cm/s]현저증가(P<0.015),교대조조치료후[(4.62±1.26)ml/s;(9.26±1.58)cm/s]역유현저증가(P<0.05).뇌혈관외주조력급림계압력인격매효낭조화대조조치료후[(1826±258)Pa.s/ml;(6.02±1.84)kPa;(1926±253)Pa.s/ml;(7.03±1.43)kPa]교치료전[(2132±323 Pa.s/ml),(7.26±1.68)kPa;(2058±278)Pa.s/ml,(7.84±1.36)kPa]명현강저(P<0.05).결론 인격매효낭치료급성뇌경사환자료효호,능명현개선뇌혈류관주,강저뇌순배조력,감소신경공능결손,종이체도치료뇌경사적목적,작위뇌경사적치료약물안전유효.
Objective To observe and study the clinical efficacy of lumbrukinase capsule and its effect on cerebra hemodynamics in patients with acute infarction. Methods Totally 88 patients were enrolled. This clinical trial was randomly double-blind and parallel controlled. The patients with acute infarction were divided into two groups. All patients recieved same basic treatment; The treatment goup trented by oral administration of lumbruki-nase capsule then scoring the condition of neural functional deficits before and after the treatment; meanwhile the ce-rebrovascular dynamics index (CVDI) of the patients were measured. Results ①The neural functional deficits of patients in trial group tended to be repaired. The effective rate( ER) was 90. 5% ,but the control group's ER was 77.5%. ②The total cerebral blood flow and velocityin the focal side of brain after the treatment in the treatment group showed a statistically significant increase,compared with those before the treatment(P<0.05),and even with the co up(P<0.05). And the cerebral vascular resistance(R) and critical pressure showned a statistically significant decrease(P<0.05). Conclusions These results reveal that the lumbrukinase capsule is effective in re-lieving the neural functional deficits of patients with acute infarction by reducing cerebral circulation's resistance. It is a safe and effective drug treating cerebral infarction.
